AKT1 and breast cancer: At this moment, it remains unclear whether activation of the PI-3 K/Akt signaling by any means, such as PIK3CA mutation or phosphatase and tensin homolog (PTEN) deletion in addition to erbB2/erbB3 receptors, would also enhance expression of Survivin in breast cancer cells.